Full Results of Merck’s Zerbaxa Trial Show Drug Is on Par With Meropenem as Pneumonia Treatment

During a presentation at a European medical conference, Merck & Company released late-stage data that showed that Zerbaxa (ceftolozane and tazobactam) was on par with meropenem as a treatment for adult patients with ventilated nosocomial (hospital-acquired) pneumonia.